Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Cervicitis Workup

  • Author: Arthur T Ollendorff, MD; Chief Editor: Michel E Rivlin, MD  more...
 
Updated: Nov 04, 2014
 

Approach Considerations

The Centers for Disease Control and Prevention (CDC) recommends testing on self- or clinician-collected endocervical and vaginal swab specimens, as well as on urine specimens.[10] Nucleic acid amplification testing (NAAT) is the most sensitive and specific for gonorrheal and chlamydial infections,[1, 10] and it also allows for testing on the widest variety of specimen types.[10]

There is an association between a finding of leukorrhea (>10 white blood cells [WBCs] under microscopic high-power field [HPF] examination of vaginal fluid) and cervical chlamydial and gonococcal infection.[1] If the woman doesn’t have inflammatory vaginitis, leukorrhea may be a sensitive indicator of cervical inflammation with a high negative predictive value.[1]

Note that although some experts believe the presence of elevated polymorphonuclear leukocytes on endocervical Gram stain is useful in diagnosing cervicitis, no standard criterion exists and it is generally unavailable in clinical settings. Moreover, the positive predictive value is low for C trachomatis and N gonorrhoeae.

Gonococcal cervical infection can be diagnosed from the presence of gram-negative intracellular diplococci (GNID) in endocervical fluid. However, only 50% of affected women have this finding.[1]

If genital ulcer disease is observed, exclude the diagnosis of syphilis by serologic testing or consider performing a biopsy. Adolescents presenting with urinary symptoms should be tested for sexually transmitted and urinary tract infections. Adequate follow up should be established to ensure timely treatment.[19]

In cases of suspected or documented treatment failure, perform culture and antimicrobial susceptibility testing.

Screening in high-risk populations

Women at risk for sexually transmitted infections (eg, women with multiple partners, sexually active women aged 25 years or younger [including adolescents], women with a history of previous sexually transmitted infections [STIs], and pregnant women) should be annually screened for gonorrhea and chlamydia. Such screening in this population has been proven to be cost effective.

HSV screening

General screening for herpes simplex virus (HSV) is not recommended, because no evidence demonstrates that serologic tests for HSV antibody improve health outcomes or symptoms or reduce disease transmission. However, in individuals whose sexual partners are known to be infected with HSV-2, screening can be offered.

Next

Identification of Infectious Agents

Because the causes of vulvovaginitis and cervicitis overlap, the initial diagnostic approaches to the 2 conditions are identical. Assess the appearance of vaginal secretions, measure the pH of the secretions, and perform microscopy with isotonic sodium chloride solution and 10% potassium hydroxide (KOH) along with a whiff test.

T vaginalis

Infection with T vaginalis usually produces a thin, purulent, frothy, and malodorous discharge and can cause vulvar erythema and edema. The cervix can be erythematous and may have punctate hemorrhages (ie, colpitis macularis or “strawberry cervix”).

The diagnosis is suggested if microscopy of cervical secretions reveals 10-30 leukocytes per oil immersion field. The diagnosis is confirmed by observation of the motile, flagellated protozoan on the normal saline wet mount under the microscope. However, note that trichomonads are observed under microscopy in only about 50% of cases (ie, low sensitivity); therefore, additional testing is recommended in symptomatic women with negative microscopy findings.[1]

On cytology, Trichomonas is a pear-shaped extracellular organism with a pale nucleus and red granules in its cytoplasm (see the following image).

Pap stain, high power (under oil immersion), showi Pap stain, high power (under oil immersion), showing 2 pear-shaped structures representing Trichomonas. Small, pale nuclei and cytoplasmic granules are present.

Other tests for trichomoniasis in women include a nucleic acid probe test that evaluates for T vaginalis, Gardnerella vaginalis, and Candida albicans (available in about 45 min) in vaginal secretions[20] and a test that uses an immunochromatographic capillary flow dipstick technology (available in about 10 min). However, despite the tendency toward greater sensitivity in these tests compared with those requiring wet mount preparation, there is the potential for false positives, particularly in areas with a low prevalence of disease.[20]

Another sensitive and available technique for trichomoniasis is culture of vaginal secretions, generally used when the condition is suspected but not confirmed by microscopy.[20] Liquid-based testing has enhanced sensitivity but also has the potential for false-positive results requiring other confirmatory tests. Techniques modified from detection of gonorrhea and chlamydia to detect trichomoniasis include a modified polymerase chain reaction (PCR) assay and transcription-mediated amplification.[20]

C trachomatis and N gonorrhoeae

If cervicitis is suspected or mucopurulent cervicitis is observed, then cervical discharge is collected for culture and, optionally, for Gram stain. The microscopic finding of gram-negative intracellular diplococci has a sensitivity of 60% and a specificity of more than 90% for gonorrhea. The observation of more than 30 leukocytes per oil immersion field is highly suggestive of chlamydia and gonorrhea.

Although culture is still regarded as the criterion standard, many alternative techniques for the diagnosis of gonorrhea and chlamydia are available. They include enzyme immunoassay (EIA), direct fluorescent antibody [DFA] staining, DNA probe, and PCR assay.

Nucleic acid amplification tests (NAATs) are preferred over the other tests, because they are highly sensitive and specific for diagnosing gonococcal and chlamydial infections.[1] NAATs can be performed on vaginal, cervical, and urine samples; the presence of 10 or more WBCs in vaginal fluid in the absence of trichomoniasis suggests endocervical inflammation from gonococcal or chlamydial infection.[1]

The advantages of alternative techniques over conventional cultures include reduced turnaround time and lack of dependence on the complex and expensive systems needed to culture chlamydia and gonorrhea. Alternative techniques also possess the ability to detect both C trachomatis and N gonorrhoeae with the same sample. The main disadvantage of all the nonculture diagnostic techniques is the inability to assess microbial resistance. Nonetheless, many clinic- and hospital-based practices have already stopped using cultures and have switched to these alternative modalities.

Herpesvirus

If typical grouped vesicles mixed with small ulcers are observed, in addition to a typical history, the diagnosis of HSV infection can be made on clinical grounds alone. For atypical ulcers or first infection, attempt definitive diagnosis by culture.

However, although culture is considered the criterion standard for the diagnosis of herpes simplex, alternative techniques (eg, cytology, antigen detection, DNA probe) are also used. On cytology, HSV consists of cells with multinucleation, margination of chromatin, and nuclear molding. Nuclear inclusions may be appreciated (see the image below).

Papanicolaou (Pap) stain, high power, showing the Papanicolaou (Pap) stain, high power, showing the Herpes simplex virus (HSV) infecting cells with multiple nuclei, intranuclear inclusions, and margination of the chromatin to the outer portion of the nuclei.

Serology currently has no role in the diagnosis of HSV infection, because of cross-reactivity between HSV types 1 and 2 in the assays. Newer, type-specific glycoprotein g1 and g2 serologic assays exist, but they are not yet for routine diagnostic use.

Human papillomavirus

If the patient has no gross lesions on the cervix and previously received adequate cervical cancer screening (negative cervical cytology within past 3 years or negative cytology and HPV testing within the past 5 years), no further testing for HPV is necessary. If the patient has not had screening for cervical cancer, she should be screened according to age-appropriate guidelines. The United States Preventive Services Task Force (USPSTF), American College of Obstetrics and Gynecology (ACOG), and American Cancer Society (ACS) recommend HPV testing combined with Pap testing every 5 years in women aged 30-65 years; however, the Pap test every 3 years alone for this age group is also acceptable.[16, 17, 18] For women aged 21-29 years, Pap test screening for cervical cancer is recommended every 3 years. However, screening is not recommended in women younger than 21 years.[16, 17, 21]

Women with abnormal cervical cancer screening results should be managed according to the American Society of Cytology and Cervical Pathology recommendations.[22, 23]

Previous
 
 
Contributor Information and Disclosures
Author

Arthur T Ollendorff, MD Director of Medical Education, Department of Obstetrics/Gynecology, Mountain Area Health Education Center; Clinical Professor, Department of Obstetrics/Gynecology, University of North Carolina School of Medicine

Arthur T Ollendorff, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, Association of Professors of Gynecology and Obstetrics, North Carolina Medical Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Nicole W Karjane, MD Associate Professor, Department of Obstetrics and Gynecology, Virginia Commonwealth University Medical Center

Nicole W Karjane, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, Association of Professors of Gynecology and Obstetrics, North American Society for Pediatric and Adolescent Gynecology

Disclosure: Nothing to disclose.

Chief Editor

Michel E Rivlin, MD Former Professor, Department of Obstetrics and Gynecology, University of Mississippi School of Medicine

Michel E Rivlin, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Medical Association, Mississippi State Medical Association, Royal College of Surgeons of Edinburgh, Royal College of Obstetricians and Gynaecologists

Disclosure: Nothing to disclose.

Acknowledgements

A David Barnes, MD, PhD, MPH, FACOG Consulting Staff, Department of Obstetrics and Gynecology, Mammoth Hospital (Mammoth Lakes, California), Pioneer Valley Hospital (Salt Lake City, Utah), Warren General Hospital (Warren, Pennsylvania), and Mountain West Hospital (Tooele, Utah)

A David Barnes, MD, PhD, MPH, FACOG is a member of the following medical societies: American College of Forensic Examiners, American College of Obstetricians and Gynecologists, American Medical Association, Association of Military Surgeons of the US, and Utah Medical Association

Disclosure: Nothing to disclose.

Jeffrey B Garris, MD Chief, Assistant Professor, Department of Obstetrics and Gynecology, Division of Urogynecology and Reconstructive Pelvic Surgery, Tulane University School of Medicine

Jeffrey B Garris, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Institute of Ultrasound in Medicine, American Medical Association, American Urological Association, Association of Professors of Gynecology and Obstetrics, Louisiana State Medical Society, Royal Society of Medicine, and Sigma Xi

Disclosure: Nothing to disclose.

Sabrina R Kendrick, MD, FACP Assistant Professor, Department of Internal Medicine, Rush University Medical Center; Director, Screening Clinic, The CORE Center; Consulting Staff, Division of Infectious Diseases, John H Stroger Hospital of Cook County

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Anita B Varkey, MD Assistant Professor, Department of Medicine, Loyola University Medical Center; Associate Program Director, Internal Medicine Residency; Medical Director, General Internal Medicine Clinic, Loyola Outpatient Center

Anita B Varkey, MD is a member of the following medical societies: American College of Physicians and Society of General Internal Medicine

Disclosure: Nothing to disclose.

References
  1. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010: diseases characterized by urethritis and cervicitis. Available at http://www.cdc.gov/std/treatment/2010/urethritis-and-cervicitis.htm. Accessed: May 17, 2012.

  2. Paavonen J. Chlamydia trachomatis infections of the female genital tract: state of the art. Ann Med. 2012 Feb. 44(1):18-28. [Medline].

  3. Taylor BD, Darville T, Ferrell RE, Kammerer CM, Ness RB, Haggerty CL. Variants in toll-like receptor 1 and 4 genes are associated with Chlamydia trachomatis among women with pelvic inflammatory disease. J Infect Dis. 2012 Feb 15. 205(4):603-9. [Medline]. [Full Text].

  4. Oakeshott P, Aghaizu A, Hay P, Reid F, Kerry S, Atherton H. Is Mycoplasma genitalium in women the "New Chlamydia?" A community-based prospective cohort study. Clin Infect Dis. 2010 Nov 15. 51(10):1160-6. [Medline].

  5. Bjartling C, Osser S, Persson K. Mycoplasma genitalium in cervicitis and pelvic inflammatory disease among women at a gynecologic outpatient service. Am J Obstet Gynecol. 2012 Jun. 206(6):476.e1-8. [Medline].

  6. McGowin CL, Anderson-Smits C. Mycoplasma genitalium: an emerging cause of sexually transmitted disease in women. PLoS Pathog. 2011 May. 7(5):e1001324. [Medline]. [Full Text].

  7. Centers for Disease Control and Prevention. STD trends in the United States: 2010 national data for gonorrhea, chlamydia, and syphilis. Available at http://www.cdc.gov/std/stats10/trends.htm. Accessed: October 24, 2012.

  8. Centers for Disease Control and Prevention. Trichomoniasis – CDC fact sheet. Available at http://www.cdc.gov/std/trichomonas/STDFact-trichomoniasis.htm. Accessed: October 24, 2012.

  9. Centers for Disease Control and Prevention. Genital HPV infection – CDC fact sheet. Available at http://www.cdc.gov/std/HPV/STDFact-HPV.htm. Accessed: October 24, 2012.

  10. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010: chlamydial infections. Available at http://www.cdc.gov/std/treatment/2010/chlamydial-infections.htm. Accessed: May 18, 2012.

  11. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010: gonococcal infections. Available at http://www.cdc.gov/std/treatment/2010/gonococcal-infections.htm. Accessed: May 18, 2012.

  12. Burnett AM, Anderson CP, Zwank MD. Laboratory-confirmed gonorrhea and/or chlamydia rates in clinically diagnosed pelvic inflammatory disease and cervicitis. Am J Emerg Med. 2012 Sep. 30(7):1114-7. [Medline].

  13. Centers for Disease Control and Prevention. Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years--United States, 2005-2008. MMWR Morb Mortal Wkly Rep. 2010 Apr 23. 59(15):456-9. [Medline].

  14. World Health Organization. Sexually Transmitted Infections. October 2007. Available at http://www.who.int/mediacentre/factsheets/fs110/en/index.html.

  15. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005 Sep 17-23. 366(9490):991-8. [Medline].

  16. American College of Obstetricians and Gynecologists. New cervical cancer screening recommendations from the U.S. Preventive Services Task Force and the American Cancer Society/American Society for Colposcopy and Cervical Pathology/American Society for Clinical Pathology. Available at http://www.acog.org/About ACOG/Announcements/New Cervical Cancer Screening Recommendations.aspx. Accessed: October 24, 2012.

  17. American Cancer Society. American Cancer Society guidelines for the early detection of cancer. Available at http://www.cancer.org/healthy/findcancerearly/cancerscreeningguidelines/american-cancer-society-guidelines-for-the-early-detection-of-cancer. Accessed: October 24, 2012.

  18. US Preventive Services Task Force. Screening for cervical cancer. Available at http://www.uspreventiveservicestaskforce.org/uspstf/uspscerv.htm. Accessed: October 24, 2012.

  19. Prentiss KA, Newby PK, Vinci RJ. Adolescent female with urinary symptoms: a diagnostic challenge for the pediatrician. Pediatr Emerg Care. 2011 Sep. 27(9):789-94. [Medline].

  20. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010: diseases characterized by vaginal discharge. Available at http://www.cdc.gov/std/treatment/2010/vaginal-discharge.htm. Accessed: May 18, 2012.

  21. Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol. 2004 Apr. 103(4):619-31. [Medline].

  22. {Guideline} American College of Obstetricians and Gynecologists. Practice bulletin no. 140: management of abnormal cervical cancer screening test results and cervical cancer precursors. Obstet Gynecol. 2013 Dec. 122(6):1338-67. [Medline].

  23. Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013 Apr. 121(4):829-46. [Medline].

  24. Centers for Disease Control and Prevention. Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep. 2012 Aug 10. 61(31):590-4. [Medline]. [Full Text].

  25. Centers for Disease Control and Prevention. Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep. 2007 Apr 13. 56(14):332-6. [Medline]. [Full Text].

  26. Centers for Disease Control and Prevention. 2010 sexually transmitted diseases surveillance. Available at http://www.cdc.gov/std/stats10/gonorrhea.htm. Accessed: November 6, 2012.

  27. Centers for Disease Control and Prevention. Chlamydia screening among sexually active young females enrollees of health plans - United States, 2000-2007. MMWR Weekly. April 17, 2009. 58(14):362-365. [Full Text].

  28. Griffith WF, Stuart GS, Gluck KL, Heartwell SF. Vaginal speculum lubrication and its effects on cervical cytology and microbiology. Contraception. 2005 Jul. 72(1):60-4. [Medline].

  29. Katz VL, Lentz GM, Lobo RA, Gershenson DM. Comprehensive Gynecology. 5th ed. Mosby; 2007. 598-600.

  30. Kirkcaldy RD, Augostini P, Asbel LE, et al. Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD Surveillance Network, 2009-2010. Emerg Infect Dis. 2012 Jun. 18(6):939-43. [Medline]. [Full Text].

  31. Schiffman M, Khan MJ, Solomon D, Herrero R, Wacholder S, Hildesheim A. A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst. 2005 Jan 19. 97(2):147-50. [Medline].

 
Previous
Next
 
Normal cervix
Cervix of a lactating woman without sexually transmitted infections. The patient had twice given birth vaginally.
Cervical cellularity (ectopy), which is often present in adolescents, allows for greater adherence of infectious organisms in the cervix. The risk of acquiring acute salpingitis for a sexually active 15-year-old is 1:8, compared with 1:80 for women aged 24 years and older.
Signs of chlamydial cervicitis on speculum examination may include mucopurulent endocervical discharge and spontaneous or easily induced endocervical bleeding or any zones of ectopy.
In women with gonococcal cervicitis, the cervix may show mucopurulent or purulent cervical discharge and easily induced cervical bleeding.
Herpes simplex virus (HSV) cervicitis may involve the exocervix or endocervix, and it may be symptomatic or asymptomatic. Usually, the cervix appears abnormal to inspection, with diffuse vesicular lesions, ulcerative lesions, erythema, or friability.
T vaginalis can have a characteristic "frothy" gray or yellow-green vaginal discharge and pruritus. The occurrence of cervical petechiae, or "strawberry cervix," is a classic presentation that is seen in less than 2% of cases. T vaginalis may also infect the Skene glands and the urethra and may be asymptomatic in women.
Papanicolaou (Pap) stain, high power, showing the Herpes simplex virus (HSV) infecting cells with multiple nuclei, intranuclear inclusions, and margination of the chromatin to the outer portion of the nuclei.
Pap stain, high power, showing human papillomavirus (HPV) infecting a cell with a dark, wrinkled nucleus surrounded by a clear cytoplasmic halo.
Pap stain, high power (under oil immersion), showing 2 pear-shaped structures representing Trichomonas. Small, pale nuclei and cytoplasmic granules are present.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.